Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA/industry compliance task force

This article was originally published in The Gray Sheet

Executive Summary

The agency's Office of Regulatory Affairs is deciding whether to implement the task force's proposal to allow manufacturers a prescribed amount of time to respond to an FD-483 report before the agency issues a warning letter ("The Gray Sheet" March 16, p. 14), industry reps say. The "grassroots" task force had proposed giving firms 15 days to respond before a warning letter went out. The group is expected to meet this fall in Rockville, Maryland to discuss development of a questionnaire for FDA inspectors and inspected companies to offer feedback on the agency's practices of preannounced inspections, annotated 483s and warning letter "close-out" correspondence; methods of keeping agency field personnel up to date on emerging technologies; and development of additional guidance on submitting premarket submissions to FDA
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel